General Assembly Meeting Thursday, May 5th 10:00 – 13:00

General Assembly Meeting - 2022

A virtual (Zoom) and face-to-face meeting in Paris, France

followed by Lunch

Other Logistical information to follow nearer the time




The 2020 GA meeting which normally takes place in May was postponed to November 4th due to the global pandemic. The November 4th meeting which was virtual saw 20 attendees and lasted an hour as most of the GA mandated task/decisions were addressed by way of votes prior to the meeting. Chaired by Interim Chairman Dr Bernd Friede, the meeting though brief was effective with some key decisions taken as follows:

Some highlights:

  • Executive Committee: A new Executive team was endorsed with the 2nd Vice-Chairman becoming the Chairman and Secretary General maintained to ensure continuity
  • Non-EU letter of Access Fees: Letter of Access fees and administration fees for non-EU REACH-Like regulations per substance, per legal entity for non-MARA members was established
  • Members involvement in Non-EU regulations: MARA members wishing to register substances in non-EU REACH-like regulations will only pay administration fees as they own the data generated by MARA
  • Technical update: Three dossiers updated this year lead to a new classification for manganese based UVCB’s
  • 2020 Workplan and budget were ratified in Q1, 2020 via round robin votes.

Prenatal Developmental Toxicity Study in the Han Wistar Rat/MnCl2/OECD 414/Inhalation/GLP

The purpose of this study was to detect effects on the pregnant rat, development of the embryo and fetus consequent to exposure of the pregnant female via inhalation route (by nose-only, flow-past exposure) for risk assessment purposes and for gathering data necessary for modeling work safety scenarios.

A recovery group of non-mated females in all dose groups and the control group were observed for reversibility, persistence or delayed occurrence of systemic toxic effects in the lung- information necessary for establishing workplace task rotation strategies.

Four groups of 22 mated females (main study animals) and 6 non-mated females (recovery animals) were treated with manganese dichloride once daily, for 6 hours per day. Mated females were treated from day 6 post coitum (implantation) to day 20 post coitum (the day prior to Caesarean section) and recovery animals from day 1 to 15 of a concurrent treatment period at target dose levels of:

Group 1:               0 µg/L air (control group)

Group 2:               5 µg/L air

Group 3:             15 µg/L air

Group 4:             25 µg/L air

All mated females were sacrificed on day 21 post coitum and the fetuses were removed by Caesarean section. For the recovery animals, three females per group were sacrificed after four weeks and three females per group were sacrificed after eight weeks of the recovery period.


Based on these results, the NOAEL (No Observed Adverse Effect Level) as well as the NOEL (No Observed Effect Level) for the toxicity in pregnant females were considered to be 5 µg/L air.

In non-pregnant females, the NOEL for systemic toxicity was established at 15 µg/L air, whereas the NOAEL was established at 25 µg/L air.

Although the fetal thyroids increased in size were found at the dose level of 25 µg/L air, which caused adverse maternal toxicity, the causal correlation for these observations was unclear. Also, the outcome of the fetal finding for the postnatal live could not be conclusively established based on the results of this study. Therefore, the NOEL as well as NOAEL for prenatal developmental toxicity was considered to be 15 µg/L air.

« Back to studies

About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)